We’re pleased to share an exclusive interview with our CEO featured by ABA – INVEST in AUSTRIA! In this article, we talk about Cycuria Therapeutics‚ journey as a startup from Graz and how we’re developing a cutting-edge targeted cancer therapy for patients in need.
From our vision for precision oncology to why Austria is the perfect place for biotech innovation, this interview dives into the passion and science driving our mission.
👉 Read the full interview with our CEO here.
📢 We’re proud to unveil exciting news from Cycuria Therapeutics. We’ve secured grant funding from two leading Austrian national bodies, FFG and AWS, and today
Cycuria has been selected to present at the Startup Spotlight Stage during the upcoming BIO-Europe Spring partnering conference! Our presentation will showcase Cycuria’s pioneering approach
We are thrilled to announce that Cycuria has been honored with the SPIRIT Startup Award in the Health category ! This prestigious recognition highlights our
Cycuria will be attending the upcoming American Society of Hematology (ASH) Annual Meeting in San Diego from December 7- December 10. We look forward to
At Cycuria, we are dedicated to developing novel cytokine-based therapies to dramatically improve outcomes for patients living with cancer, offering hope where traditional treatments have fallen short.